Regeneron Pharmaceuticals And Sanofi Present Late-Breaking Data From NOTUS Confirmatory Phase 3 COPD Trial Of Use Of Dupixent; Presented At ATS And Published In New England Journal of Medicine
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals and Sanofi presented late-breaking data from the NOTUS Phase 3 COPD trial, showing that Dupixent significantly reduced exacerbations and improved lung function in patients with uncontrolled COPD. The results were presented at ATS and published in the New England Journal of Medicine.
May 20, 2024 | 6:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals presented positive data from the NOTUS Phase 3 COPD trial, showing Dupixent significantly reduced exacerbations and improved lung function. This supports Dupixent's potential as a new treatment for COPD.
The positive results from the NOTUS trial support Dupixent's potential as a new treatment for COPD, which could lead to increased sales and revenue for Regeneron.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Sanofi presented positive data from the NOTUS Phase 3 COPD trial, showing Dupixent significantly reduced exacerbations and improved lung function. This supports Dupixent's potential as a new treatment for COPD.
The positive results from the NOTUS trial support Dupixent's potential as a new treatment for COPD, which could lead to increased sales and revenue for Sanofi.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100